Bare lymphocyte syndrome

A rare immunodeficiency disorder

Bare lymphocyte syndrome (BLS) is a rare immunodeficiency disorder characterized by the absence or significant reduction of major histocompatibility complex (MHC) molecules on the surface of lymphocytes. This condition leads to severe immune system dysfunction, as MHC molecules are crucial for the immune system's ability to recognize and respond to foreign antigens.

Classification

Bare lymphocyte syndrome is classified into two main types based on the specific MHC molecules affected:

• Type I BLS: This type involves a deficiency in MHC class I molecules. It is often associated with chronic lung infections and granulomatous skin lesions.

• Type II BLS: This type involves a deficiency in MHC class II molecules. It is more severe than Type I and is characterized by recurrent infections, failure to thrive, and often leads to early childhood mortality if untreated.

Pathophysiology

The pathophysiology of bare lymphocyte syndrome involves genetic mutations that affect the expression of MHC molecules on the surface of antigen-presenting cells. In Type I BLS, mutations typically occur in genes responsible for the transport and processing of MHC class I molecules. In Type II BLS, mutations affect the transcription factors necessary for the expression of MHC class II molecules.

Clinical Features

Patients with bare lymphocyte syndrome present with a variety of clinical features depending on the type:

• Type I BLS: Patients may experience recurrent respiratory tract infections, bronchiectasis, and skin lesions. Despite the absence of MHC class I molecules, these patients often have normal T-cell counts.

• Type II BLS: This type presents with severe combined immunodeficiency-like symptoms, including recurrent bacterial, viral, and fungal infections, chronic diarrhea, and failure to thrive.

Diagnosis

Diagnosis of bare lymphocyte syndrome involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Key diagnostic tests include:

• Flow cytometry to assess the expression of MHC molecules on lymphocytes.
• Genetic testing to identify mutations in genes associated with MHC expression.
• Immunological assays to evaluate the function of T-cells and other immune components.

Treatment

The treatment of bare lymphocyte syndrome is primarily supportive and may include:

• Antibiotic prophylaxis to prevent infections.
• Immunoglobulin replacement therapy to provide passive immunity.
• Hematopoietic stem cell transplantation (HSCT) is the only curative treatment, particularly for Type II BLS.

Prognosis

The prognosis for patients with bare lymphocyte syndrome varies depending on the type and severity of the condition. Type I BLS generally has a better prognosis with appropriate management, while Type II BLS often requires early intervention with HSCT to improve survival outcomes.

Related pages

• Immunodeficiency
• Major histocompatibility complex
• Hematopoietic stem cell transplantation